RAPP

Rapport Therapeutics Stock Analysis

AI Rating

Good
  • Quality3/10
  • Growth↓ 4/10
  • Value↑ 6/10
Rapport Therapeutics sales and earnings growth
RAPP Growth
Neutral
  • Revenue Y/Y↓ 0.00%
  • EPS Y/Y↑ 13.67%
  • FCF Y/Y↓ -16.84%
Rapport Therapeutics gross and profit margin trends
RAPP Profitability
Neutral
  • Gross margin ↑ 100.00%
  • EPS margin↓ -536.40%
  • ROIC 5Y↓ 0.00%
Rapport Therapeutics net debt vs free cash flow
RAPP Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↓ NA

Rapport Therapeutics stock volatility is in-line with the overall market. We give it a Great risk rating.

↗ More Biotechnology stocks